anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neonatal death often occurs in tertiary Neonatal Intensive Care Units (NICUs). In China, end-of-life-care (EOLC) does not always involve parents. The aim of this study is to evaluate a parent support intervention to integrate parents at the end of life of their infant in the NICU.

A quasi-experimental study using a non-randomized clinical trial design was conducted between May 2020 and September 2021. Participants were infants in an EOLC pathway in the NICU and their parents. Parents were allocated into a family supportive EOLC intervention group or a standard EOLC group based on their wishes. Primary outcomes were depression (Edinburgh Postnatal Depression Scale for mothers; Hamilton Depression rating scale for fathers) and satisfaction. Student t-test for continuous variables and the Chi-square test categorical variables were used in the statistical analysis.
PURPOSE: A composition containing non-toxic natural antibacterial plant extracts, plant essential oils and compounds derived from the plant extracts inhibiting the growth of Pityrosporum ovale as a pathogenic fungus is provided. The composition has excellent growth inhibiting activity against yeast or pathogenic fungi may reside on the dermal integument, preferably against Pityrosporum ovale and low toxicity and thus can be used as a natural antibacterial agent. CONSTITUTION: An anti-Pityrosporum ovale composition comprises 0.1 to 20% by weight of a plant extract or a plant essential oil and one or more pharmaceutically acceptable composition such as excipients or diluents. The plant extract is obtained by extracting one or more plants in one or more solvents selected from the group consisting of organic solvents, distilled water and alcohol. One or more plants are selected from the group consisting of Myristica fragrans, Lavandula hybrida, Citrus sinensis, Cupressus sempervirens, Santalum album, Ocimum basilicum, Thujapsis dolabrata var. hondai, Citrus unshiu, Foeniculum vulgare, Cinnamomum sieboldii, Cinnamomum cassis, Asarum heterotropoides, Gentianopsis barbata and Zingiber officinale.
GPR55 is a receptor for lysophosphatidylinositols (LPIs) in digestive metabolites. Overnutrition leads to obesity, insulin resistance, and increased LPI levels in the plasma. The involvement of LPIs and GPR55 in adiposity, hepatic steatosis, and atherosclerosis has been previously elucidated. However, the therapeutic efficacy of GPR55 antagonists against obesity-induced airway inflammation has not been studied. The present study investigated whether CID16020046, a selective antagonist of GPR55, could modulate obesity-induced airway inflammation caused by a high-fat diet (HFD) in C57BL/6 mice. Administration of CID16020046 (1 mg/kg) inhibits HFD-induced adiposity and glucose intolerance. Analysis of immune cells in BALF showed that CID16020046 inhibited HFD-induced increase in immune cell infiltration. Histological analysis revealed the HFD induced hypersecretion of mucus and extensive fibrosis in the lungs. CID16020046 inhibited these HFD-induced pathological features. qRT-PCR revealed the HFD-induced increase in the expression of Ifn-γ, Tnf-α, Il-6, Il-13, Il-17A, Il-1β, Nlrp3, and Mpo mRNAs in the lungs. CID16020046 inhibited the HFD-induced increases in these genes. The expression levels of adipokines were regulated by the HFD and CID16020046. AdipoQ in the lungs and gonadal white adipose tissue was decreased by the HFD and reversed by CID16020046. In contrast, Lep was increased by the HFD and suppressed by CID16020046. The findings suggest the potential application of the GPR55 antagonist CID16020046 in obesity-induced airway inflammation.
Surgical treatment alone, consisting of arthroscopic rotator cuff repair. Ultrasound postoperatively at 1 year.
Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.
BACKGROUND AND PURPOSE: Total hip arthroplasty (THA) can be performed through various surgical approaches, including direct anterior (DAA). DAA-THA may offer faster recovery but carries a higher risk of complications, which may be mitigated by surgeon volume and experience. We examined the association of surgeons' annual surgical volume with major complications after DAA-THA in a population-based sample.
METHODS: A population-based retrospective cohort study was carried out on primary DAA-THA patients in Ontario between April 2016 and March 2021. We used restricted cubic splines to visually define the association between annual DAA surgeon volume and the risk of major surgical complications (fractures, dislocations, infections, and revisions) within 1 year of surgery. We further compared the complication rates amongst different DAA volume categories (< 30, 30-60, and > 60 cases/year).
RESULTS: The study encompassed 9,672 DAA-THA patients (52% female, median age 67 years). We showed a sharp decline in the probability of complications as the surgical volume of DAA-THA increased within the lower range of 0-30 cases/year; the probability slightly increased after the surgical volume exceeded 60 cases/year. The overall complication rates were 3.09%, 2.24%, and 2.18% for the surgical experience group of < 30 cases/year, 30-60 cases/year, and > 60 cases/year, respectively.
CONCLUSION: There was an inverse relationship between surgical volume and complication rates in DAA-THA within the lower volume ranges. Maintaining a surgical volume of at least 30 DAA-THA cases/year can minimize complications, emphasizing the importance of surgical volume in this approach.
Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: To report a "critical phase" (between osteotomy completion and correction beginning) that will frequently lead to the reversible intraoperative neurophysiological monitoring (IOM) change during posterior vertebral column resection (PVCR) surgery.
METHODS: The study sample consisted of 120 patients with severe spine deformity who underwent PVCR and deformity correction surgeries. Those patients were recruited consecutively from 2010 to 2018 January in our spine center. The detailed IOM data (the amplitude of MEP & SEP) and its corresponding surgical points were collected prospectively. Early and long-term postoperative neurologic outcomes were assessed for the following functions: motor, sensory, and pain at immediate postoperative and 1-year post-operation in this cases series.
RESULTS: A total of 105 (105/120) patients presented varying degrees of IOM reduction in the critical phase; the mean IOM amplitude retention vs rescue rate was 27% ± 11.2 versus 58% ± 16.9, P < 0.01 (MEP) & 34% ± 8.3 versus 66% ± 12.4 P < 0.01 (SEP). Patients with postoperative spinal deficits often had a significantly longer IOM-alerting duration than the patients without (p < 0.01, Mann-Whitney U-test), and IOM-alerting duration greater than 39.5 min was identified as an independent predictor of the risk of postoperative spinal deficits.
CONCLUSIONS: The reversible IOM events probably often appear in the critical phase during PVCR surgery. The new postoperative spinal deficits are possible for patients without satisfied IOM recovery or alerting duration greater than 39.5 min. Timely and suitable surgical interventions are useful for rescuing the IOM alerts.
A natural composition that includes  C. osmophloeum  and  C. pinnatifida.  The  C. osmophloeum  is an aqueous extract of  Cinnamomum osmophloeum  leaves. The  Crataegus pinnatifida  is an aqueous extract of  C. pinnatifida  fruit. The weight ratio of the  C. osmophloeum  to the  C. pinnatifida  is 1:0.05-2, the preferred ratio is 1:0.5-1.5, and the optimal ratio is 1:0.9-1.1. The pharmaceutical composition has an α-glucosidase inhibition effect. The natural composition can further inhibit α-amylase to regulate the absorption of blood glucose and carbohydrate.
A method for delivering glucose and insulin to a subject to improve carbohydrate metabolism. It is desirable to improve liver storage of glycogen, and in general to reduce excess fatty tissue in the liver. The method delivers a large amount of glucose accompanied by a series of bursts of insulin to the subject over a period of time. The amount of insulin in each burst, the interval between bursts and the amount of time to deliver each burst to the subject are selected so that the cellular processing of glucose is improved in the subject. The glucose is delivered in dose portions over an extended period of hours, typically providing a roughly even rate of glucose input during the insulin administration. Treatments are repeated over multiple days. For most subjects, an improvement in resting amount of carbohydrate metabolism is seen.
Due to demographic changes, a growing number of elderly patients with comorbidities will require spine surgery in the next decades. However, age and multimorbidity have been associated with considerably worse postoperative outcomes, and is often associated with surgical invasiveness. Full-endoscopic spine-surgery (FESS), as a cornerstone of contemporary minimally invasive surgery, has the potential to mitigate some of these disparities. Thus, we conducted an analysis of all FESS cases at a national center. Utilizing the Charlson Comorbidity index (CCI) ≥ 3 as a frailty surrogate we separated patients in two groups for patients with and without comorbidities. Patients with (CCI) ≥ 3 exhibited a higher age (p < 0.001), and number of comorbidities (p < 0.001) than the control group. Thereafter, a propensity score matching was done to adjust for potential confounders. Postoperative safety measures in emergency department utilization, and clinic readmission did not significantly differ between the groups. Furthermore, patients of both groups reported similar postoperative pain improvements. However, patients with a (CCI) ≥ 3 were treated as inpatients more often (p < 0.001), had a higher length of stay (p < 0.001) and a smaller functional improvement after at a chronic postoperative timepoint (p = 0.045). The results underline safety and efficacy of FESS in patients with comorbidities. Additionally, they provide guidance for preoperative patient counselling and resource utilization when applying FESS in frail patients.
Background: Chemotherapy may lead to peripheral neuropathy up to 40% in cancer survivors, especially in some types of patients with cancer. The effect of acupuncture, an ancient Chinese medicine technique, was recognized by the World Health Organization (WHO) in the treatment of several diseases. The postulated mechanisms associated with acupuncture in analgesia or neurogenesis are still under investigation. Considering a moderate recommendation for duloxetine in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) based on based on neuropathic pain, and a few treatment options with evidence for CIPN, acupuncture might be another option. Nowadays, only small scale pilot studies provided initial proof of acupuncture in CIPN, particularly in decreasing neuropathic pain and improving neurotoxicity, the study aims to determine the beneficial effects of acupuncture on CIPN with a large-scale, multicenter, randomized sham-controlled clinical trial. Furthermore, the aim of the study will provide evidence for the clinical therapeutic guideline of CIPN in the future.

Methods: This three-armed, multicenter, randomized, parallel, sham-controlled clinical trial will conduct in three centers in Taiwan. We will randomly assign 234 eligible patients into three groups, an acupuncture group (n=90), a sham-controlled group (n=90), and a waitlist-controlled group (n=54). Each subject maintains the regular treatments of cancer except the chemotherapeutic agents designed in our design. The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture. The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints. The primary outcome measurement will be the changes in the FACT-Ntx subscale from baseline to 20th acupuncture sessions. The secondary outcome will be the changes in BPI-SF average pain score from baseline to 20th acupuncture sessions. The third outcome will be the changes of target forces by von-Frey filament test at each point in hands and feet from baseline to 20th acupuncture treatments. from baseline to 20th sessions. FACT-Ntx scale and BPI-SF average pain score will be measured at four time-points, including baseline, the end of the 12th treatments, the end of the 20th treatments, and the end of the study at the 12th week. The von-Frey filament test will be measured at three-time points, including baseline, the end of the 20th treatments, and the end of the study at the 12th week.
The present invention relates to a process of preparing macromolecular capsules. In particular, the invention relates to the use of a template with a permeable shell and an impermeable core for preparing macromolecular capsules. The process of the present invention relates to infiltrating macromolecules such as polymers into a permeable shell and then crosslinking the macromolecules to form a macromolecular network within the pores of the permeable shell. In some cases, the permeable shell and impermeable core can both be removed to yield hollow capsules. The invention involves the use of macromolecules which may be conjugated to one or more functional molecules. In some cases the macromolecules used in the invention are conjugated to biologically active molecules to form particles useful for applications including, but not limited to, drug delivery and controlled release.
PURPOSE:An anemic remedy for nasotracheal administration, containing human erythropoietin as an active constituent, capable of exhibiting good percutaneous absorbability and effective for treating anemia. CONSTITUTION:An anemic remedy for nasotracheal administration containing human erythropoietin (hereinafter abbreviated to human EPO) as an active constituent. The human EPO is a glycoprotein produced in the kidney and a humoral hematopoietic factor, acting on erythroblastic stem cells of the marrow and promoting differentiation of the cells to erythrocytic cells. The human EPO which is slightly absorbed in the stomach and intestines has been recently found to exhibit good absorbability by nasotracheal administration. The human EPO is mixed with a surfactant and aqueous and/or nonaqueous medium to form a pharmaceutical for nasotracheal administration, e.g. solution, suspension, ointment, etc., as the anemic remedy. Furthermore, a gel base, e.g. cellulosic derivative, natural gum, etc., can be added, as desired, to afford a gel pharmaceutical.
The present inventors conducted investigations in order to develop a metal oxide which enables effective UV-screening; i.e. which has excellent screening ability against ultraviolet rays, particularly against long-wavelength ultraviolet rays, as well as excellent visible-light transmission; and to provide a UV-screening composition that contains the metal oxide and can be applied to external use. As a result, the present inventors have found that zinc oxide produced by a particular method has a characteristic form; i.e., primary particles having an average particle diameter of 50-100 nm aggregate in a planer shape, and a ratio represented by lnT360nm/lnT400nm (Txnm: transmittance of transmitted light of x nm) of 10 or more, and exerts excellent screening effect against long-wavelength ultraviolet rays as well as excellent visible-light transmission. The present invention has been accomplished based on this finding. The zinc oxide of the present invention effectively exerts the above-described excellent characteristics; i.e. UV-screening effect and transparency, and can be applied to a composition for external use such as make-up cosmetics or sunscreen cosmetics.
We conduct an intervention study in a sample of 200 knowledge-workers who engage in different lunch break activities for 15-minutes per day, two weeks in a row. We randomly assign participants to three experimental conditions: 1) exposure to nature, 2) relaxation and 3) control group (lunch break spent as usual). Online questionnaires before and after the intervention assess long term changes regarding recovery processes and the major outcome variables. Before, during and after the intervention, SMS and paper-pencil questionnaires measure the same constructs four times a day with fewer items. We also measure blood pressure and collect saliva samples to map cortisol excretion across the intervention period. A timed experimental task (i.e., the Alternative Uses Task) is used to examine differences in creativity between the three groups after the intervention period.

By combining the knowledge of work and environmental psychology about recovery and restorative experiences, by merging three recovery perspectives (settings, processes, and outcomes) and by using data triangulation, we produce valid results that broaden our view on mechanisms underlying recovery and enhance our understanding about their links to psychological, behavioural and physiological outcomes, resulting in a more comprehensive picture of work stress recovery in general.
PURPOSE: To obtain a percutaneously absorbable pharmaceutical preparation useful as a therapeutic agent for hypertension, angina pectoris and arrhythmia and capable of administering atenolol through the skin into the body. CONSTITUTION: This percutaneously absorbable pharmaceutical preparation contains 2-60wt.% atenolol having β1 blocking actions and 1-30wt.% nonionic surfactant and/or compound of terpenes as an absorbefacient. For example, a tacky agent base ingredient (e.g. an acrylic copolymer) is thermally melted and atenolol and an absorbefacient [e.g. polyoxyethylene (4) lauryl ether and 1-menthol] are then added to provide the percutaneously absorbable preparation. The obtained plaster is spread on a support and covered with a liner to form a polymer layer containing the atenolol. The resultant polymer layer is spread on an ethylene film undergoing the surface oxidation treatment, regulated to an area corresponding to about 10-100mg and applied for 12-48hr for use.
For topical use only. Not for oral, ophthalmic, or intravaginal use.

Atralin Gel should be applied once daily, before bedtime, to the skin where acne lesions appear, using a thin layer to cover the entire affected area. Atralin Gel should be kept away from the eyes, the mouth, paranasal creases, and mucous membranes. Application of excessive amounts of gel will not provide incremental efficacy.

Patients treated with Atralin Gel may use cosmetics, but the areas to be treated should be cleansed thoroughly before the medication is applied.

When treating with Atralin Gel, caution should be exercised with the use of concomitant topical over-the-counter preparations, topical medications, medicated or abrasive soaps and cleansers, products that have strong drying effect, and products with high concentrations of alcohol, astringents, spices, or lime. Particular caution should be exercised with acne preparations containing benzoyl peroxide, sulfur, resorcinol, or salicylic acid. Allow the effects of such preparations to subside before use of Atralin Gel has begun.
Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is  11 C,  18 F,  64 Cu,  124 I,  99 Tc,  111 In or GdIII and its method of use for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors. Preferably the photosensitizer is a tumor avid tetrapyrollic photosensitizer, e.g. a porphyrin, chlorin or bacteriochlorin, e.g. pheophorbides and pyropheophorbides. Such conjugates have extreme tumor avidity and can be used to inhibit or completely destroy the tumor by light absoption. The integrin is usually αvβ3, α5β1, αvβ5, α4β1, or α2β1. Preferably, the antagonist is an RGD peptide or another antagonist that may be synthetic such as a 4-{2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethyloxy}-benzoyl]amino-2-(S)-amino-ethyl-sulfonylamino group. Such compounds provide tumor avidity and imaging ability thus permitting selective and clear tumor imaging.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic excellent in both hair dressing properties such as hair adjustability and set preservability and good feeling by bringing the cosmetic to contain a polysaccharide and a high molecular polyethylene glycol. SOLUTION: This hair cosmetic is brought to contain (A) preferably an anionic polysaccharide (e.g. λ-type carrageenan, etc.), and (B) a polyethylene glycol having 500,000-5,000,000 average molecular weight. The cosmetic is preferably brought to contain 0.05-5 wt.% of the ingredient A and 0.01-2 wt.% of the ingredient B. Further, to emulsify the system, the cosmetic is brought to contain 65-90 wt.% of water, 1-15 wt.% of a lubricant (e.g. liquid paraffin, etc.), and 0.1-4 wt.% of a surfactant (a higher fatty acid salt and a polyoxyethylene alkyl ether, etc.).
It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool.
Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.
BACKGROUND: Nutrition plays a vital role in the outcome of critically ill children, particularly those with AKI. Currently, there are no established guidelines for children with AKI treated with continuous RRT (CRRT). A thorough understanding of the metabolic changes and nutritional challenges in AKI and CRRT is required. Our objective was to create clinical practice points for nutritional assessment and management in critically ill children with AKI receiving CRRT.
METHODS: PubMed, MEDLINE, Cochrane, and Embase databases were searched for articles related to the topic. Expertise of the authors and a consensus of the workgroup were additional sources of data in the article. Available articles on nutrition therapy in pediatric patients receiving CRRT through January 2023.
RESULTS: On the basis of the literature review, the current evidence base was examined by a panel of experts in pediatric nephrology and nutrition. The panel used the literature review as well as their expertise to formulate clinical practice points. The modified Delphi method was used to identify and refine clinical practice points.
CONCLUSIONS: Forty-four clinical practice points are provided on nutrition assessment, determining energy needs, and nutrient intake in children with AKI and on CRRT on the basis of the existing literature and expert opinions of a multidisciplinary panel.